Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Clinical Pharmacology: Advances and Applications

Volumn 6, Issue 1, 2014, Pages 51-59

  Nagelschmitz, J ^a   Blunck, M ^a   Kraetzschmar, J ^a   Ludwig, M ^a   Wensing, G ^a   Hohlfeld, T ^b  

^a BAYER PHARMA AG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cyclooxygenase 1; Intravenous acetylsalicylic acid; Oral acetylsalicylic acid; Pharmacodynamics; Pharmacokinetics; Platelet aggregation; Thromboxane formation

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; PLACEBO; THROMBOXANE B2;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG URINE LEVEL; EX VIVO STUDY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84897898917     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S47895     Document Type: Article

References (26)

1. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693-11697.
2. Cham BE, Ross-Lee L, Bochner F, Imhoff DM. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit. 1980;2(4):365-372.
3. Smith WL. Molecular mechanisms of aspirin action. Drug News Perspect. 1991;4:362-366.
4. Prosdocimi M, Finesso M, Gorio A, et al. Coronary and systemic 6-ketoprostaglandin F1 alpha and thromboxane B2 during myocardial ischemia in dog. Am J Physiol. 1985;248(4 Pt 2):H493-H499.
5. Cerletti C, Gambino MC, Garattini S, de Gaetano G. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels. J Clin Invest. 1986;78(1):323-326.
6. FitzGerald GA, Lupinetti M, Charman SA, Charman WN. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. J Pharmacol Exp Ther. 1991;259(3):1043-1049.
7. Muir N, Nichols JD, Clifford JM, Stillings MR, Hoare RC. The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. Curr Med Res Opin. 1997;13(10):547-553.
8. Rowland M, Rielgelma S. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. J Pharm Sci. 1968;57(8):1313-1319.
9. Broome TA, Brown MP, Gronwall RR, Casey MF, Meritt KA. Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. Can J Vet Res. 2003;67(4):297-302.
10. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983;67(6):1174-1177.
11. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
12. Gerrard JM. Measurements of 6-keto-prostaglandin F1 alpha and throm-boxane B2 in bleeding time blood: relation to bleeding and vascular disorders? Can J Physiol Pharmacol. 1989;67(8):922-928.
13. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108(5):542-547.
14. European Medicines Agency. ICH Topic E9. Statistical principles for clinical trials. Available from: http://www.ema.europa.eu/pdfs/human/ich/036396en.pdf. Accessed June 6, 2011.
15. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
16. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296(5567): 539-541.
17. Cerletti C, Gambino MC, Bucchi F, Rajtar G, Riva E, de Goetano G. Comparison of the effects of oral and intravenous aspirin administration on platelet and peripheral vascular cyclo-oxygenase activity: studies in rats and in man. Agents Actions Suppl. 1986;20:239-248.
18. Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32(23): 2999-3054.
19. Ito S, Oka R, Tsuchida A, Yoshioka H. Disposition of single-dose intravenous and oral aspirin in children. Dev Pharmacol Ther. 1991; 17(3-4):180-186.
20. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low- dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383.
21. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366-1372.
22. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3): 676-688.
23. Dillinger JG, Drissa A, Sideris G, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012;164(4):600-606.
24. Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10(7):1220-1230.
25. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewel of the drug target. Blood. 2012;119(15):3595-3603.
26. Vejar M, Hackett D, Brunelli C, et al. Comparison of low-dose aspirin and coronary vasodilators in acute unstable angina. Circulation. 1990;81 Suppl I:I4-I11.